Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMmotion151: Atezolizumab + Bevacizumab vs Sunitinib in Advanced RCC
NCT02420821Phase 3Completed
- Sponsor
- Roche
- Start
- May 2015
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of atezolizumab in renal cell carcinoma (RCC), sponsored by Roche. Started May 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02420821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420821.